AGA’s Biosimilars in IBD Care series has four case-based scenarios where GI experts discuss how to they address concerns raised by inflammatory bowel disease (IBD) patients about biosimilars or about switching therapies from originator biologics. Learn:
- How to discuss the similarities and differences between biosimilars and biologics.
- What your patients need to understand about using biosimilars for their treatment.
- What concerns you may hear from patients and how to allay their fears.
In the opening case-based scenario, Drs. Mark Osterman, Adam Cheifetz and Douglas Wolf will teach you effective ways to explain the difference between biologics and biosimilars to a patient who doesn’t understand why you are recommending a biosimilar.
